… about how we might protect against SARS-CoV-2 variants in those individuals who are
immunosuppressed and therefore unable to mount responses even after two vaccine doses. …

… SARS-CoV-2 shares more than 70% genetic similarity … SARS coronavirus 1 (SARS-COV-1),
which caused the 2003 outbreak. Although SARS-CoV-1 was more pathogenic, SARS-CoV-…

… to SARS-CoV-2 and the various vaccine platforms being used to develop the SARS-CoV-2
vaccines… Understanding the mechanism of action of the various candidate vaccines is the key …

… PATIENTS AND METHODS We analyzed the titer magnitude of the IgG antibodies directed
against SARS ‑CoV ‑2 spike antigen 14 to 21 days after the second dose of the BNT162b2 …

… Replication-deficient chimpanzee adenovirus-based vaccines have shown promise for
several emerging viruses, and given their simian origin, they circumvent concerns for vector-…

… pre-existing clinical experience with any coronavirus vaccine and with multiple steps of …
in a licensed vaccine before [2,3]. There is a strong need for vaccines against SARS-CoV-2 as …

… SARS-CoV-2, multiple SARS-CoV-2 vaccines with demonstrated safety and efficacy in phase
III clinical trials are available. The most promising vaccines … The promise of mRNA vaccines …

… Therefore these approaches promise to ultimately optimize parenteral vaccines for the
induction of strong, protective IgA responses at the mucosal compartments [Citation6]. Among the …

… anti-SARS coronavirus vaccines, since the last pandemic nearly 17 years ago, have opened
the doors to rationally develop vaccine … Indeed, the promise of future vaccine development …

… become vaccinated and exposed to SARS-CoV-2, and thus some recent vaccine trials make
use … [ 135 ] Taken together, intranasal delivery shows promise, but further data is required to …